Sugi Predict

Sugi Predict / Compounds / Clogestone Acetate

Clogestone Acetate

Clogestone Acetate

SCHEMBL282096

CC(=O)O[C@@H]1C=C2C(Cl)=C[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(OC(C)=O)C(C)=O)[C@@]2(C)CC1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 7/20 0.70
▸ CYP3A4 P08684 7/20 0.70
▸ AR P10275 6/20 0.70
▸ PGR P06401 6/20 0.70
▸ SMN1; SMN2 Q16637 4/20 0.70
▸ MAPK1 P28482 3/20 0.70
▸ ALDH1A1 P00352 3/20 0.70
▸ CHRM2 P08172 3/20 0.70
▸ NPSR1 Q6W5P4 3/20 0.70
▸ HIF1A Q16665 2/20 0.70
▸ CHRM1 P11229 2/20 0.70
▸ USP2 O75604 2/20 0.70
▸ ADORA3 P0DMS8 1/20 0.70
▸ THRB P10828 1/20 0.70
▸ TBXA2R P21731 1/20 0.70
▸ CYP2C19 P33261 1/20 0.70
▸ ADRA1A P35348 1/20 0.70
▸ LMNA P02545 5/20 0.61
▸ CYP2C9 P11712 3/20 0.61
▸ MAPT P10636 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clogestone Acetate SCHEMBL29857472 1.00 NR3C1 (0.70) NR3C1CYP3A4ARPGRSMN1; SMN2
SCHEMBL13595777 0.89 NR3C1 (0.73) NR3C1CYP3A4ARPGRSMN1; SMN2
SCHEMBL29400001 0.88 AR (0.70) NR3C1CYP3A4ARPGRSMN1; SMN2
SCHEMBL1406037 0.87 NR3C1 (0.73) NR3C1CYP3A4ARPGRSMN1; SMN2
SCHEMBL1405851 0.87 NR3C1 (0.73) NR3C1CYP3A4ARPGRSMN1; SMN2
SCHEMBL1405853 0.87 NR3C1 (0.73) NR3C1CYP3A4ARPGRSMN1; SMN2
SCHEMBL8000538 0.87 NR3C1 (0.73) NR3C1CYP3A4ARPGRSMN1; SMN2
Chlormadinone Acetate SCHEMBL11795531 0.82 AR (1.00) NR3C1CYP3A4ARPGRSMN1; SMN2
Chlormadinone Acetate SCHEMBL4948575 0.82 AR (1.00) NR3C1CYP3A4ARPGRSMN1; SMN2
Chlormadinone Acetate SCHEMBL15046 0.82 AR (1.00) NR3C1CYP3A4ARPGRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160008376-A1 Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders BIOCOPEA LIMITED (GB) 2016-01-14 — — US claimed
WO-2016005599-A1 COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS BIOCOPEA LIMITED (GB) 2016-01-14 — — WO claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 — — US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 — — US claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 — — US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
CN-1187042-C Plaster which contains steroids, and method for the production and use thereof LTS LOHMANN THERPAIE SYSTEME A (DE) 2005-02-02 — — CN claimed
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 — — EP disclosed
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2026-02-05 — — US disclosed
US-12465564-B2 Oral and nasal compositions and methods of treatment AQUESTIVE THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20250339367-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2025-11-06 — — US disclosed
US-12403090-B2 Oral film compositions and dosage forms having precise active dissolution profiles AQUESTIVE THERAPEUTICS, INC. (US) 2025-09-02 — — US disclosed
US-20250255780-A1 SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES AQUESTIVE THERAPEUTICS, INC. (US) 2025-08-14 — — US disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 — — WO disclosed
CN-1178668-A Cooperate therepeutic-pregnendione and estrin excitant for preventing bony defect PFIZER (US) 1998-04-15 — — CN disclosed
WO-1997044063-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES NEUROMEDICA, INC. (US) 1997-11-27 — — WO disclosed
CN-1165654-A Combination therapy to treat osteoporosis-polyphosphonates or progesting and extrogen agonists PFIZER (US) 1997-11-26 — — CN disclosed
EP-0792645-A1 Combination therapy to treat osteoporosis PFIZER INC. (US) 1997-09-03 — — EP disclosed
EP-0791356-A1 Combinations of droloxifene with progestins for the treatment of osteoporosis PFIZER INC. (US) 1997-08-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES SORD, SLC6A13, CACNA1A NR3C1 4229/4885CYP3A4 143/4885AR 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.